Publications by authors named "Eulalia Sola-Porta"

Article Synopsis
  • Recent studies suggest that using kidneys from HCV positive donors can lead to acceptable results for HCV negative recipients, although acceptance of these donors hasn't widely increased in clinical practice.
  • This study examined kidney transplants from 44 non-viremic and 25 viremic HCV positive donors from 2013 to 2021, finding no significant differences in transplant outcomes between the two groups.
  • While recipients from viremic donors had a higher rate of HCV seroconversion, peri-transplant treatment with direct antiviral agents (DAA) appeared to mitigate risks associated with viremia, demonstrating overall similar outcomes to those from non-viremic donors.
View Article and Find Full Text PDF

Membranous nephropathy (MN) is a common cause of nephrotic syndrome after kidney transplantation (KT); however, scarce is known regarding post-KT thrombospondin type-1 domain-containing 7A (THSD7A)-positive MN. Herein, we report on a 72-year-old woman with end-stage kidney disease due to chronic interstitial nephritis (1996). In February 2020, she received a second deceased-donor KT, achieving optimal kidney function but presenting early post-KT proteinuria, reaching up to 1800mg/24h six months after transplantation, controlled with renin-angiotensin-aldosterone system (RAAS) blockade.

View Article and Find Full Text PDF

Early hypertransaminasemia after kidney transplantation (KT) is frequent. It has been associated with the crosstalk produced between the liver and the kidney in ischemia-reperfusion situations. However, the influence of the donor type has not been evaluated.

View Article and Find Full Text PDF

Studies are urgently needed to characterize immunogenicity, efficacy, and safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines in kidney transplant (KT) recipients, excluded from major clinical trials. Complex ELISPOT and other cellular response techniques have been applied, but simpler tools are needed. An easy-to-use real-world monitoring of SARS-CoV-2 IgG antibodies against the Spike protein and QuantiFERON SARS-CoV-2 IFNγ release assay (IGRA) were performed at baseline and 28 days after the second dose in KT recipients and controls (dialysis patients and healthy ones).

View Article and Find Full Text PDF